Skip to main
TVRD

TVRD Stock Forecast & Price Target

TVRD Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 43%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

Tvardi Therapeutics's strong outlook is supported by promising developments in its product candidates TTI-101 and TTI-109, with ongoing Phase 2 trials showing potential improvements in safety and efficacy for treating idiopathic pulmonary fibrosis and hepatocellular carcinoma. The company’s robust anti-fibrotic strategy aims to address significant unmet medical needs, particularly in patients with high levels of fibrosis, raising expectations for TTI-109 due to its anticipated better tolerability compared to TTI-101. Early clinical data suggest that TTI-101 is performing well across various treatment lines, thereby enhancing its competitive positioning in the biopharmaceutical market.

Bears say

Tvardi Therapeutics Inc. is facing a negative outlook primarily due to the high competitive risk in its target markets, particularly in idiopathic pulmonary fibrosis and hepatocellular carcinoma, where established and emerging therapies may hinder its ability to achieve market share and viability. Additionally, there are concerns regarding financing, with expectations that the company will need to raise capital before reaching profitability, which could dilute existing shareholder value. The potential for clinical trial failures or unexpected safety signals further exacerbates these risks, as such setbacks could lead to asset impairments and diminished market confidence.

TVRD has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 43% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cara Therapeutics Inc (TVRD) Forecast

Analysts have given TVRD a Buy based on their latest research and market trends.

According to 7 analysts, TVRD has a Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $34.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $34.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cara Therapeutics Inc (TVRD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.